KRAS and cancer: A subsequent study demonstrated that the kinetics of EV-associatedKRAS mutant allele frequency (MAF) were deeply correlated with neoadjuvant chemotherapyresponse; 71% of patients with a lack of cancer progression showed decreased KRAS MAF,while 94% of patients with cancer progression showed no decrease in KRAS MAF[144].